Personalized Cell Therapy
Begins with You
Autologous iPSC-derived neuron replacement therapy for Parkinson’s disease
We are leveraging our in-house stem cell biology and genomics platform to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson’s disease.
Around 50% of dopamine neurons in the brain are lost before a Parkinson’s disease diagnosis. Even with the current standard of care therapy, patients can eventually develop debilitating motor complications. Our goal is to turn back the clock on Parkinson’s disease.
Our Technology
Aspen Neuroscience is leading the science of using a patient’s own cells to develop personalized cell replacement therapies. This approach has the potential to restore lost function.
Our lead product ANPD001 has received IND clearance and Fast Track designation from the U.S. Food and Drug Administration, and is currently under investigation in the Phase 1/2a ASPIRO trial for the treatment of Parkinson’s disease.
Aspen’s autologous cell development platform starts with a small sample of the patient’s own skin cells, which are then reprogrammed to iPSCs unique to each patient, before differentiation into their final cell type for therapeutic delivery.
To treat greater numbers of patients with their own cells, Aspen Neuroscience is developing a robust, scalable, and automated biomanufacturing system at its new 22,000 square foot facility for GMP manufacturing of induced pluripotent stem cell (iPSC)-derived cell therapies.
Before being implanted, Aspen’s autologous cells are evaluated at every stage of the manufacturing process by Aspen’s proprietary genomics platform, which includes several machine learning based genetic tests to evaluate cell quality.
Our Commitment to Patients
Patients helped found our company, are depending on us and are at the center of every decision we make.
